肺康方对肺癌化疗患者造血功能、免疫功能及肿瘤标志物的影响  

Effect of Feikang prescription on hematopoietic function,immune function and tumor markers in patients with lung cancer undergoing chemotherapy

作　　者：邢玮[1] 郑心 曹玉风 袁少静 Xing Wei;Zheng Xin;Cao Yufeng;Yuan Shaojing

机构地区：[1]山东中医药大学第二附属医院,山东济南250001 [2]青岛海慈医疗集团,山东青岛266033

出　　处：《中医临床研究》2021年第24期107-111,共5页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察肺康方对肺癌化疗患者造血功能、免疫功能及肿瘤标志物的影响。方法:将131例纳入研究的肺癌化疗患者随机分为观察组(64例)和对照组(67例)。对照组给予包括化疗在内的西医常规治疗,观察组在对照组的基础上给予中药肺康方。治疗2个化疗周期(42 d),对比两组患者的化疗有效率,并观察两组患者的造血功能[外周血白细胞计数(White Blood Cell Count,WBC)、血红蛋白(Hemoglobin,HGB)、中性粒细胞(Neutrophil,NC)、血小板计数(Platelet,PLT)]、免疫功能[自然杀伤细胞(Natural Killer Cell,NK)、辅助性T细胞(T helper Cell 17,Th17)、调节性T细胞(Regulatory cells,Treg)及Th17/Treg]以及肿瘤相关抗原[鳞状细胞癌相关抗原(Squamous Cell Careinoma Antigen,SCC)、细胞角蛋白19片段(Cytokeratin-19-fragment,CY21-1)及神经元特异性烯醇化酶(Neuron-specific Enolase,NSE)]的变化,并观察不良反应发生情况。结果:①疗效比较:观察组临床控制率(DCR)为86.6%高于对照组65.6%,差异有统计学意义(P<0.05)。②造血功能比较:两组造血功能指标WBC、HGB、NC及PLT水平不同(F分组=14.376、16.019、21.431、24.826,P<0.05),两组指标各时间点水平不同(F时间=11.956、13.643、17.772、19.478,P<0.05),两组指标变化趋势存在差异(F交互=10.829、11.684、14.805、17.368,P<0.05)。③免疫功能比较:两组免疫功能指标NK、Th17、Treg和Th17/Treg水平不同(F分组=11.309、14.276、9.343、15.920,P<0.05),两组指标各时间点水平不同(F时间=9.487、12.851、8.825、13.274,P<0.05),两组指标变化趋势差异具有统计学意义(F交互=7.965、10.573、7.038、11.539,P<0.05)。④肿瘤相关抗原比较:两组肿瘤相关抗原SCC、CY21-1、NSE水平不同(F分组=15.337、15.628、21.389,P<0.05),两组指标各时间点水平不同(F时间=13.843、13.581、17.945,P<0.05),两组指标变化趋势比较,差异具有统计学意义(F交互=11.238、11.774、14.067,P<0.05)。⑤不良反应比较:观�Objective:To observe the effect of Feikang prescription(肺康方)on hematopoietic function,immune function and tumor markers in patients with lung cancer undergoing chemotherapy.Methods:131 cases of lung cancers patients with chemotherapy were randomly divided into the control group(64 cases)and the observation group(67 cases).The control group was given routine western medicine treatment including chemotherapy,while the observation group was given Feikang prescription on the basis of the treatment of the control group.After 2 cycles of chemotherapy(42D),the effective rate of chemotherapy was compared between the two groups.Hematopoietic function[peripheral blood white blood cell(WBC)count,hemoglobin(HGB),neutrophil(NC),platelet(PLT)count],immune function[natural killer(NK)cell,helper T cell(Th17),regulatory T cells(Treg)and Th17/Treg,as well as tumor associated antigens(SCC),cytokeratin 19 fragment(CY21-1)and neuron specific enolase(NSE)),and the occurrence of adverse reactions were observed.Results:①Comparison of effectiveness:The clinical control rate(DCR)of the observation group was 86.6%,which was higher than that of the control group,65.6%,the difference was statistically significant(P<0.05).②Hematopoiesis comparison:There were significant differences in WBC,Hb,NC and PLT between the two groups(F group=14.376,16.019,21.431 and 24.826,P<0.05).All indexes of the two groups were different at different time points(F group time=11.956,13.643,17.772 and 19.478,P<0.05),and trend of change showed significant differences(F interaction=10.829,11.684,14.805 and 17.368,P<0.05);③Comparison of immune function:There were significant differences in NK,Th17,Treg and Th17/Treg between the two groups(F group=11.309,14.276,9.343 and 15.920,P<0.05).All indexes of the two groups were different at different time points(F group time=9.487,12.851,8.825 and 13.274,P<0.05,and trend of change showed significant differences(Finteraction=7.965,10.573,7.038 and 11.539,P<0.05);④Comparison of tumor associated antigens:The levels o

关 键 词：肺康方 肺癌 化疗 造血功能 免疫功能 肿瘤标志物 疗效 

分 类 号：R273[医药卫生—中西医结合]